#### Check for updates

#### **OPEN ACCESS**

EDITED BY Marilia Seelaender, University of São Paulo, Brazil

REVIEWED BY Rosalia Padovani, Santa Casa of São Paulo, Brazil Ning Ding, Central South University, China

\*CORRESPONDENCE Lianghui Li Ilhxmzs@sina.com Lijuan Chen xmetchenlijuan@163.com

<sup>†</sup>These authors have contributed equally to this work

RECEIVED 31 October 2023 ACCEPTED 22 February 2024 PUBLISHED 01 March 2024

#### CITATION

Shen J, Zhang H, Jiang H, Lin H, He J, Fan S, Yu D, Yang L, Tang H, Lin E, Li L and Chen L (2024) The effect of micronutrient on thyroid cancer risk: a Mendelian randomization study. *Front. Nutr.* 11:1331172. doi: 10.3389/fnut.2024.1331172

#### COPYRIGHT

© 2024 Shen, Zhang, Jiang, Lin, He, Fan, Yu, Yang, Tang, Lin, Li and Chen. This is an openaccess article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

# The effect of micronutrient on thyroid cancer risk: a Mendelian randomization study

Jiali Shen<sup>1†</sup>, Hong Zhang<sup>2†</sup>, Hongzhan Jiang<sup>1</sup>, Huihui Lin<sup>1</sup>, Jiaxi He<sup>3</sup>, Siyue Fan<sup>1</sup>, Doudou Yu<sup>1</sup>, Liping Yang<sup>1</sup>, Hui Tang<sup>4</sup>, Ende Lin<sup>5</sup>, Lianghui Li<sup>5</sup>\* and Lijuan Chen<sup>5</sup>\*

<sup>1</sup>School of Nursing, Fujian University of Traditional Chinese Medicine, Fuzhou, China, <sup>2</sup>School of Clinical Medicine, Fujian Medical University, Fuzhou, China, <sup>3</sup>School of Medicine, Xiamen University, Xiamen, China, <sup>4</sup>Department of Nuclear Medicine, Zhongshan Hospital of Xiamen University, School of Medicine, Xiamen, China, <sup>5</sup>Department of General Surgery, Zhongshan Hospital of Xiamen University, School of Medicine, Xiamen, China

**Background:** The effect of micronutrients on thyroid cancer has been studied in observational studies, however, the cause of relationships has not yet been determined. Thyroid cancer was the subject of a Mendelian randomization (MR) analysis of micronutrients. Aimed to determine whether micronutrient intake has a causal impact on the chance of developing thyroid cancer.

**Methods:** We used a Mendelian randomization (MR) analysis with two samples. Our circulation levels of Cu, Ir, Zn, Ca, VD, and VC were reflected by genetic variations reported from GWAS in individuals of European ancestry. For the GWAS outcome of thyroid cancer. Sensitivity studies that included MR-Egger, weighted median/mode tests, and a more open selection of variations at a genome-wide sub-significant threshold were added to our inverse-variance weighted (IVW) MR study.

**Results:** Using the IVW approach, we did not find evidence that any of the micronutrients to thyroid cancer (Cu: odds ratio [OR = 0.88, p = 0.41]; Zn: odds ratio [OR = 0.87, p = 0.40]; Ir: odds ratio [OR = 1.18, p = 0.39]; Ca: odds ratio [OR = 1.12, p = 0.43]; VC: odds ratio [OR = 0.95, p = 0.22]; VD: odds ratio [OR = 0.89, p = 0.04]). The heterogeneity (p > 0.05) and pleiotropy (p > 0.05) testing provided confirmatory evidence for the validity of our MR estimates.

**Conclusion:** This study does not provide evidence that supplementation with micronutrients including Cu, Ir, Zn, Ca, VD, and VC can prevent thyroid cancer.

#### KEYWORDS

thyroid cancer, copper, iron, zinc, calcium, vitamin D, vitamin C, Mendelian randomization

# Introduction

The global incidence of thyroid cancer (TC) is experiencing a steady increase, primarily attributed to the heightened utilization of diagnostic imaging and surveillance. According to data obtained from the International Agency for Research on Cancer (IARC) in 2020, the Global Cancer Observatory reported a total of 586,000 newly diagnosed cases of TC worldwide, accounting for 3.0% of all newly diagnosed cancer cases (1). Furthermore, TC

ranked 9th among population-based cancer incidence rates. In the United States, thyroid carcinoma is projected to rank 13th in terms of newly diagnosed tumors in 2022, with an estimated 440,000 cases (2). TC has been recognized as a cancer type with a significant financial burden on patients. Many observational studies have indicated the potential importance of micronutrients and their supplementation in preventing and alleviating cancer (3).

Copper (Cu) plays a crucial role in respiration, free-radical defense, and immune regulation, primarily attributed to its structural involvement in cuproenzymes (4). Additionally, Cu is believed to initiate angiogenesis in tumor cells (5). However, elevated levels of Cu can potentially stimulate growth, proliferation, and carcinogenesis by causing DNA damage through the action of toxic hydroxyl radicals (6).

Iron (Ir) is crucial for maintaining human health due to its involvement in oxidation–reduction reactions and its significant role in various physiological processes (7). Ongoing investigations are being conducted to explore the association between IR and thyroid cancer. Notably, thyroid cancer cells secrete hepcidin, a hormone that can suppress the expression of Ferroportin (FPN) and result in elevated intracellular Ir levels, consequently facilitating cancer cell proliferation. The majority of existing research supports the notion of a correlation between Ir and thyroid cancer (8, 9).

Zinc (Zn) is an essential trace metal with structural roles in regulatory proteins, as an enzyme cofactor, and as a signaling molecule. Zn is essential for thyroid hormone metabolism and has a potential relationship with cancer (10). Serum Zn concentrations are significantly reduced in many malignant tumors, including thyroid cancer. Zn levels in PTC and follicular carcinoma are lower than that in healthy individuals (11).

Calcium (Ca) is a mineral mainly found in bones. Intracellular Ca ions act as second messengers to regulate various physiological processes in cells, such as cell proliferation, motility, apoptosis, and other physiological processes. Some studies have found that serum Ca ions can be a protective factor for tumors (12). The thyroid gland plays a role in calcium metabolism and regulation, by secreting when needed and the thyroid stimulating hormones (TSHs) are key to regulating the metabolism of the thyroid gland to produce both T4 (thyroxine) and T3 (tri-iodothyronine) (13).

Vitamin D (VD) has a variety of physiological functions, such as regulating calcium metabolism, regulating cell growth and differentiation, regulating immunity, anti-tumor activity, and other functions (14). Some studies have analyzed and found that VD levels are significantly associated with the risk of thyroid cancer, VD may be a protective factor in the development of thyroid cancer.

Vitamin C (VC) is a necessary nutrient that regulates endothelial nitric oxide synthase and causes the neutrophil oxidative burst to maintain microcirculatory homeostasis and decrease microcirculatory pro-inflammatory signaling (15). Additionally, there is proof that consuming vitamins with antioxidant qualities, such as VC and VD, may have some positive impact on illnesses connected to the thyroid (16). It has been shown that both hyper- and hypothyroidism can affect the concentrations of the vitamins involved in the scavenging of free radicals (17).

Unfortunately, the findings are not entirely consistent and the conclusions of most studies predominantly rely on observational studies. Rigorously designed randomized controlled trials (RCT) are the gold standard for discerning causality and can effectively address potential confounders. However, due to ethical constraints, external

validity limitations, difficulty in double-blind design, interference from internal and external factors, insufficient statistical efficacy, and the need for significant cost and Time. The likelihood of conducting randomized controlled trials is low.

In conclusion, the relationship between thyroid cancer and micronutrients remains a new approach to be elucidated. As the number of large-scale genome-wide association studies (GWAS) is increasing, Mendelian randomization (MR) can MR is an epidemiological and genetic research method that can utilize the natural environment to infer causality of different phenotypes (18). Research methodology that can simulate causation and more precisely measure the impact of particular factors on outcomes by using genetic diversity found in nature as a randomized experiment (19).

We decided to conduct a Mendelian Randomization (MR) analysis of these micronutrients' potential causative effects because well-powered randomized control trials (RCT) evaluating their preventive and therapeutic potential are lacking. The well-known causal inference technique known as MR makes use of genetic variations as supporting variables (20). We want to provide fresh insight into thyroid cancer prevention by using this method to detangle the causal relationships between Cu, Ir, Zn, Ca, VC, and VD exposure and thyroid malignant tumors.

# Material and Methods

## Study design

The GWAS summary statistics about thyroid cancer and 6 micronutrients (including Cu, Ir, Zn, Ca, VC, and VD) were collected from publicly available data sources and analyzed to estimate the genetic causal relationship through MR (Figure 1).

# Determination of the instrumental variables

Three crucial aspects underlie the validity of genetic instruments: (I) Association hypothesis: There is a strong correlation between SNPs and exposure factors. (II) Independence hypothesis: SNPs are independent of confounding factors. (III) Exclusivity assumption: SNPs can only have an effect on outcomes through exposure factors (21).

# Selection of the instrumental variables

Significant SNPs were screened from the pooled GWAS data for Cu, Ir, Zn, Ca, VC, and VD ( $p < 5 \times 10^{-8}$ , Linkage disequilibrium [LD]  $r^2 < 0.01$ , Genetic distance = 10,000 KB). To satisfy the first hypothesis of MR, that instrumental variables are strongly correlated with exposure, we determined the presence of weak instrumental variable bias by calculating the F statistic (F=beta<sup>2</sup>/se<sup>2</sup>) for each SNP, with F > 10 indicating that a weak instrumental variable is not present (22). Since the SNPs used in MR follow the principle that offspring alleles are randomly assigned from the parental generation and are highly unlikely to be influenced by the environment, we can assume that the instrumental variables are not associated with confounders and satisfy MR hypothesis II (21). In addition, this study tested for horizontal



pleiotropy by MR-Egger regression model intercept and MR-PRESSO, and p > 0.05 indicates that there is no horizontal pleiotropy, then hypothesis three is fulfilled and the instrumental variables are associated with the outcome only through exposure (23).

## Validation of the instrumental variables

TC is a complex disease and the influence of common confounding factors on the role of both needs to be fully considered. In TC, other factors such as hormones, age, gender, smoking, and alcohol consumption may act as confounding intermediate phenotypes to further influence the development of TC. It is necessary to exclude the effects of other confounding factors. We examined whether IVs might influence the occurrence of TC through other confounding factors by validating the pleiotropy of excluding IVs.

## Data extraction

#### Data source for micronutrient

We searched the literature, in the Open GWAS (24) for genetic instruments associated with Cu, Ir, Zn, Ca, VC, and VD in populations of European ancestry. For Cu GWAS, they included 2,603 European individuals. A total of 2 SNPs related to Cu were identified (Supplementary Table S1). For Ir GWAS, they included 23,986 European individuals and identified 3 significant SNPs (Supplementary Table S2). For Ca GWAS, they included 315,153 European individuals and identified 173 significant SNPs (Supplementary Table S3). For VD GWAS, they included 496,946 European individuals and identified 118 significant SNPs (Supplementary Table S4). For VC GWAS, they included 291 European individuals and identified 68 significant SNPs (Supplementary Table S5). For Zn GWAS, they included 2,603 Europeans and a total of 2 SNPs were significant (Supplementary Table S6). In the Supplementary Material, more information on these phenotypes is available.

#### Data source for thyroid cancer

The GWAS summary data for TC were extracted from FinnGen, including 989 patients and 217,803 controls of European ancestry. The Cancer Registry data were used to identify cases of TC, according to the code C73 of the International Classification of Diseases-10.

## MR analyses

For each instrumental variable, the Wald ratio was used to evaluate the influence of exposure on the result. Then, we used the inverse variance weighted (IVW) method to combine each instrumental variable's effect size. This method is based on the premise that instruments can only affect a result through exposure and not through any other channel (25). The weighted median and MR-Egger methods were employed to supplement IVW estimates. A stricter instrument *p*-value threshold was set if the estimations from the methods used in our investigation were inconsistent (26). All MR analysis approaches have consistent MR results, which could provide more reliable predictions in a wider range of scenarios (27). The MR analysis was combined using a random-effect model.

## Sensitivity analyses

The heterogeneity was evaluated using Cochrane's Q value from the IVW approach, with a *p*-value <0.05 indicating statistical significance (28). The MR-Egger intercept and MR-PRESSO methods were used to detect horizontal pleiotropy (directional pleiotropy was assumed to exist if p < 0.05) (23), MR-PRESSO includes three components: (I) identification of horizontal pleiotropy; (II) horizontal pleiotropy correction by the elimination of outliers; (III) analyzing the causal estimates before and after the outlier correction to determine whether there are any discrepancies. A leave-one-out approach was employed to evaluate the effect of a particular SNP on the outcome of the MR analysis (28).

The MR analysis was performed by the R packages "TwoSampleMR" (version 0.5.6) and "MRPRESSO" (version 1.0) in the R software (version 4.2.0).

# Results

To investigate the causal association between Cu, Ir, Zn, Ca, VC, and VD-related SNPs and thyroid cancer, we conducted a two-sample MR study using genetic data from participants of European descent. Our analysis involved utilizing three different methods for estimating instrumental variables (IVs), including the IVW, WM, and MR-Egger. By evaluating interactions between these inputs and outcomes, our goal was to assess the validity of inferring a causal relationship (Table 1).

We found little evidence in favor of the genetically predicted Cu, Ir, Zn, Ca, VC, and VD concentrations having a large effect on thyroid cancer risk (Figure 2).

In MR analysis at the  $p < 5 \times 10^{-8}$  level, we found that the effect value of serum Cu on TC was [*OR*=0.88, 95% CI=(0.65–1.20), p = 0.41], which did not support a causal effect of Cu on TC.

The IVW method of the analysis showed an effect value of serum Ir on TC [OR = 1.18, 95% CI = (0.81–1.73), p = 0.39], which did not support a causal effect of Ir on TC. The WM method also showed a similar causal effect [OR = 1.23, 95% CI = (0.82–1.84), p = 0.32]. A similar causal effect of [OR = 1.10, 95% CI = (0.50–2.41), p = 0.85] was shown in the MR-Egger analysis method. The MR-Egger model intercept term was 0.014, p = 0.87 and there was no evidence of any potential horizontal pleiotropy. The WM method showed a similar causal effect [OR = 1.23, 95% CI = (0.82–1.84), p = 0.32]. Scatter plots for Mendelian randomization analysis of Ir and risk of thyroid cancer are shown in Supplementary Figure S1.

The effect value of serum Zn on TC was [OR=0.87, 95% CI=(0.64–1.19), p = 0.40], which did not support a causal effect of Zn on TC.

The IVW method of the analysis showed an effect value of serum Ca on TC of [OR = 1.12, 95% CI = (0.84–1.51), p = 0.43], which did not support a causal effect of Ca on TC. The WM method showed a similar causal effect [OR = 0.91, 95% CI = (0.51–1.62), p = 0.75]. And a similar causal effect was shown in the MR-Egger analysis method [OR = 1.40, 95% CI = (0.82–2.39), p = 0.22]. No outliers were detected by MR-PRESSO (p = 0.47), and with an MR-Egger model intercept term of -0.00712, p = 0.34, there was no evidence of any potential horizontal pleiotropy. Scatter plots for Mendelian randomization analysis of Ca and risk of thyroid cancer are shown in Supplementary Figure S2.

The IVW method of the analysis showed an effect value of VC on [OR = 0.95, 95% CI = (0.87-1.03), p = 0.22], which did not support a causal effect of VC on TC. The WM method showed a similar causal effect [OR = 0.94, 95% CI = (0.83-1.07), p = 0.40]. While in the MR-Egger analysis method, a similar causal effect of [OR = 0.98, 95% CI = (0.79-1.22), p = 0.87] was shown no outliers were detected by MR-PRESSO (p = 0.14), and with an MR-Egger model intercept term of -0.02202, p = 0.72, there was no evidence of any potential horizontal pleiotropy. Scatter plots for Mendelian randomization analysis of VC and risk of thyroid cancer are shown in Supplementary Figure S3.

The IVW method of the analysis showed an effect value of VD on TC [OR = 0.89, 95% CI = (0.61–1.30), p = 0.04], which did not support a causal effect of VD on TC. The WM method showed a similar causal effect [OR = 1.17, 95% CI = (0.58–2.35), p = 0.03]. And a similar causal effect was shown in the MR-Egger analysis method [OR = 1.01, 95% CI = (0.56–1.81), p = 0.98]. No outliers were detected by MR-PRESSO (p = 0.40), and with an MR-Egger model intercept term of -0.00441, p = 0.60, there was no evidence of any potential for horizontal multicollinearity. Scatter plots for Mendelian randomization analysis of VD and risk of thyroid cancer are shown in Supplementary Figure S4.

## Sensitivity analysis results

Cochrane Q test suggested that none of the included SNPs were significantly heterogeneous (Ir: Q=0.12, p=0.73; Ca: Q=187.34,

Exposure	Outcome	n SNPs	IVW odds ratio (95% CI)	IVW p- valueª	Cochrane's Q	Cochrane's Q p-valueª	MR-Egger Intercept <sup>b</sup>	MR-Egger Intercept p-valueª
VD	Thyroid cancer	115	0.89 (0.61–1.30)	0.561	115.252	0.449	-0.004	0.599
VC	Thyroid cancer	65	0.95 (0.87-1.03)	0.219	77.3101	0.123	-0.022	0.716
Ca	Thyroid cancer	189	1.12 (0.84–1.51)	0.431	187.335	0.479	-0.007	0.342
Ir	Thyroid cancer	3	1.18 (0.81–1.73)	0.385	0.161	0.923	0.014	0.869
Cu	Thyroid cancer	2	0.88 (0.65-1.20)	0.414	0.131	0.717	NA <sup>c</sup>	NAc
Zn	Thyroid cancer	2	0.87 (0.64–1.19)	0.399	0.499	0.479	NA <sup>c</sup>	NA <sup>c</sup>

TABLE 1 Mendelian randomization estimates for the association between thyroid cancer and micronutrient.

<sup>a</sup>Nominal *p*-value.

<sup>b</sup>The MR-Egger intercept quantifies the effect of directional pleiotropy (p < 0.05, which means possible pleiotropy).

<sup>c</sup>Insufficient number of SNPs for MR-Egger analysis.

Cu, copper; Ir, iron; Ca, calcium; Zn, zinc; VD, vitamin D; VC, vitamin C; SNPs, single nucleotide polymorphisms; IVW, inverse variance weighting.

	exposure	outcome	nSNP			estimate
	VD	Thyroid Cancer	115			0.89(0.61-1.30)
	VC	Thyroid Cancer	65	-		0.95(0.87-1.03)
	Ca	Thyroid Cancer	189	- <b>-</b>		1.12(0.84-1.51)
	Fe	Thyroid Cancer	3			1.18(0.81-1.73)
	Cu	Thyroid Cancer	2			0.88(0.65-1.20)
	Zn	Thyroid Cancer	2	-8		0.87(0.64-1.19)
				0.5 1 2	3	-
FIGURE 2 Odds ratio plot for m	nicronutrient by IV	W method.				

p = 0.48; VC: Q = 77.14, p = 0.11; VD: Q = 114.96, p = 0.43). Sensitivity analysis by applying the leave-one-out method did not reveal the existence of a single SNP that strongly affected the MR analysis results, indicating that our MR analysis results were robust (Supplementary Figures S9–S12). In addition, the funnel plots were symmetrical, again confirming that our results were reliable (Supplementary Figures S5–S8).

# Discussion

This study analyzed the causal association between Cu, Ir, Zn, Ca, VC, and VD and the risk of TC using a two-sample Mundell randomization method using GWAS data from a public database and the results showed that there was no direct causal relationship.

According to certain research, PTC was favorably correlated with urine Cu levels because Cu is an active oxidation–reduction element that supports thyroid function and lipid metabolism (29). Other research, however, indicated that TSH levels monotonically decline as serum Cu levels rise (30). Co-reduction may enhance thyroid cell oxidative stress, which would inhibit thyroid hormone synthesis and lower levels of thyroid hormone in the blood. Thyroid hormones, on the other hand, may impact blood Cu levels. Our research, however, indicated that there was no clear link between copper and thyroid cancer.

Excess Ir can harm proteins, DNA, and other cellular components (31), and Ir homeostasis is crucial to the biological functions of healthy cells. Studies show that thyroid dysfunction, including hypothyroidism and hyperthyroidism, is associated with hemoglobin levels. Hyperthyroidism is linked to iron deficiency anemia by altering iron metabolism and utilization, increasing iron uptake (32). By changing iron metabolism and use, raising oxidative stress, and accelerating hemolysis, hyperthyroidism is linked to Ir deficient anemia and lowers the RBC survival rate. Hepcidin, a substance secreted by TC cells that can increase intracellular Ir retention and reduce ferroportin (FPN) expression, can encourage the growth of cancer cells. The majority of evidence points to a connection between Ir and TC, albeit the precise mechanism is unknown (8). The increasing concentration of urine Ir quartiles was found to be substantially connected with TC risk, according to Chi Zhang's study (23). This goes against what we concluded.

Numerous research have been done on zinc and thyroid, and both hypothyroidism and hyperthyroidism are thought to be related to low

zinc levels (33). There was a correlation between thyroid volume and Zn content that was positive. Zinc levels and free T3 levels had a statistically significant positive correlation in thyroid-normal patients (34). According to Chi Zhang's research, Zn is inversely related to thyroid cancer (29). We found no evidence that zinc affected the risk of thyroid cancer. This may be because the initial hypozincemia results from an inflammatory process brought on by the disease (acute phase response), is mostly seen in plasma (but not, for example, erythrocytes), and improves with time in survivors (35).

Ca has a major role in blood clotting and hormone secretion. Abdullah, J's studies have found that serum Ca ions can serve as a tumor protective factor. However, other studies suggested that there is no significant difference between calcium concentration and thyroid stimulating hormone (TSH; T3, T4) in all groups of different ages, respectively (13).

For VC, there is evidence that the consumption of vitamins with antioxidant properties, such as VC and VD might have some beneficial effects on thyroid-related pathologies (36). F. Karimi's clinical trial showed that after 3 months of VC, and placebo supplementation patients with AIT received a placebo. In comparison, no statistically significant difference was detected between the two groups in this regard (16). This agrees with what we discovered. There aren't many findings in the literature about how vitamins may contribute to the development or management of thyroid diseases (37). A randomized controlled trial found that the anti-TgAb and TSH hormone levels in the VD group were much lower than they were at the beginning of the study, indicating that VD supplementation may be effective in reducing disease activity in HT patients (38). The results of our investigation indicate that VD is not related to the emergence of TC. Consequently, additional well-controlled, sizable, longitudinal investigations are required to ascertain whether a connection can be made.

Our study has several advantages. As far as we are aware, this is the first MR investigation to assess the effects of micronutrients on TC. Such a methodology can provide more solid proof of causality between exposure and outcome and can help alleviate constraints brought on by confounding factors frequently present in conventional observational studies. Second, using the largest and most recent GWAS for metabolites allowed for the construction of a strong instrumental variable that was projected to produce unbiased MR estimates. Third, by restricting the study population to those with European ancestry, we were able to lessen the bias brought on by demographic stratification. Fourth, to verify the connections found in the data, we performed several sensitivity analyses (using the weighted median and MR-PRESSO methods, which can minimize the bias brought on by pleiotropic effects).

There are several limitations of our study. First, although we have used MR approaches to guard against confounding, we nevertheless cannot fully exclude residual bias due to unmeasured confounders, which is an established limitation of the MR approach (39). Second, as the number of micronutrient cases in our study was relatively small, we could not completely rule out the possibility that our study may not have adequate power to discover a weak association. Finally, the lack of more detailed subgroup information prevented us from performing further subgroup analyses.

The MR analysis may have identified specific micronutrients that are associated with thyroid cancer risk or outcomes. Future research could focus on conducting mechanistic studies to elucidate the underlying biological mechanisms through which these micronutrients influence thyroid cancer. This could involve *in vitro* experiments, animal models, or molecular studies to explore the pathways and molecular targets involved. Understanding the mechanisms can provide insights into potential therapeutic interventions or preventive strategies.

# Conclusion

Through this large-scale MR study, our analyses attempted to elucidate the potential of micronutrients including Cu, Ir, Zn, Ca, VC, and VD in prophylaxis of thyroid cancer using MR techniques. However, we found little evidence of a causal association between genetically predicted micronutrient concentration on thyroid cancer risk.

# Data availability statement

The original contributions presented in the study are included in the article/Supplementary material, further inquiries can be directed to the corresponding authors.

# References

1. Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global Cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. *CA Cancer J Clin*. (2021) 71:209–49. doi: 10.3322/caac.21660

2. Cancer Statistics. (2022) Siegel – 2022 – CA: a Cancer journal for clinicians – Wiley online library. Available at: https://acsjournals.onlinelibrary.wiley.com/doi/10.3322/ caac.21708 (Accessed September 26, 2023).

3. Hu M-J, He J-L, Tong X-R, Yang W-J, Zhao H-H, Li G-A, et al. Associations between essential microelements exposure and the aggressive clinicopathologic characteristics of papillary thyroid cancer. *Biometals*. (2021) 34:909–21. doi: 10.1007/s10534-021-00317-w

4. Kim MJ, Kim SC, Chung S, Kim S, Yoon JW, Park YJ. Exploring the role of copper and selenium in the maintenance of normal thyroid function among healthy Koreans. J Trace Elem Med Biol. (2020) 61:126558. doi: 10.1016/j.jtemb.2020.126558

5. Theophanides T, Anastassopoulou J. Copper and carcinogenesis. Crit Rev Oncol Hematol. (2002) 42:57–64. doi: 10.1016/S1040-8428(02)00007-0

6. Błazewicz A, Dolliver W, Sivsammye S, Deol A, Randhawa R, Orlicz-Szczesna G, et al. Determination of cadmium, cobalt, Copper, Iron, manganese, and zinc in thyroid glands of patients with diagnosed nodular goitre using ion chromatography. *J Chromatogr B Analyt Technol Biomed Life Sci.* (2010) 878:34–8. doi: 10.1016/j.jchromb.2009.11.014

# Author contributions

JS: Writing – original draft. HZ: Writing – original draft. HJ: Writing – original draft. HL: Writing – original draft. JH: Writing – original draft. SF: Writing – original draft. DY: Writing – review & editing. LY: Writing – review & editing. HT: Writing – review & editing. EL: Writing – review & editing. LL: Writing – review & editing. LC: Writing – original draft.

# Funding

The author(s) declare financial support was received for the research, authorship, and/or publication of this article. This work was supported by the nursing research project of Zhongshan Hospital affiliated with Xiamen University (2023zsyyhlky-002).

# Conflict of interest

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

# Publisher's note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

# Supplementary material

The Supplementary material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fnut.2024.1331172/ full#supplementary-material

7. Zhou Q, Xue S, Zhang L, Chen G. Trace elements and the thyroid. Front Endocrinol. (2022) 13:904889. doi: 10.3389/fendo.2022.904889

8. Zhou Q, Chen J, Feng J, Wang J. E4BP4 promotes thyroid Cancer proliferation by modulating Iron homeostasis through repression of Hepcidin. *Cell Death Dis.* (2018) 9:1–11. doi: 10.1038/s41419-018-1001-3

9. Chisholm M. The association between webs, iron and post-cricoid carcinoma. *Postgrad Med J.* (1974) 50:215–9. doi: 10.1136/pgmj.50.582.215

10. Effectiveness of zinc supplementation on Lithium-induced alterations in thyroid functions | SpringerLink. Available at: https://link.springer.com/article/10.1007/s12011-020-02356-9 (Accessed September 29, 2023).

11. Baltaci AK, Dundar TK, Aksoy F, Mogulkoc R. Changes in the serum levels of trace elements before and after the operation in thyroid cancer patients. *Biol Trace Elem Res.* (2017) 175:57–64. doi: 10.1007/s12011-016-0768-2

12. Kato I, Sun J, Hastert TA, Abrams J, Larson JC, Bao W, et al. Association of calcium and vitamin D supplementation with cancer incidence and cause-specific mortality in black women: extended follow-up of the women's health initiative calcium-vitamin D trial. *Int J Cancer.* (2023) 153:1035–42. doi: 10.1002/ ijc.34436

13. Abdullah J. Study of the relationship between calcium ion and thyroid hormones, liver enzymes in some patients of hypocalcaemia and Hypercalcaemia. *J C ontemp Med Sci.* (2015) 1:327–30.

14. Chatterjee R, Fuss P, Vickery EM, LeBlanc ES, Sheehan PR, Lewis MR, et al. Vitamin D supplementation for prevention of cancer: the D2d Cancer outcomes (D2dCA) ancillary study. *J Clin Endocrinol Metab.* (2021) 106:2767–78. doi: 10.1210/ client/dgab153

15. Anstey MH, Aljeaidi MS, Palmer R, Jacques A, Mevavala B, Litton E, et al. Intravenous vitamin C for Vasoplegia: a double-blinded randomised clinical trial (VALENCIA trial). *J Crit Care.* (2023) 78:154369. doi: 10.1016/j.jcrc.2023.154369

16. Effects of selenium and vitamin C on the serum level of Antithyroid peroxidase antibody in patients with autoimmune thyroiditis | SpringerLink. Available at: https://link.springer.com/article/10.1007/s40618-018-0944-7 (Accessed September 29, 2023).

17. The effect of hypothyroidism, hyperthyroidism, and their treatment on parameters of oxidative stress and antioxidant status. Available at: https://www.degruyter.com/ document/doi/10.1515/CCLM.2008.183/html (Accessed September 29, 2023).

18. Yang J, Wu W, Amier Y, Li X, Wan W, Yu X. Causal relationship of genetically predicted circulating micronutrients levels with the risk of kidney stone disease: a Mendelian randomization study. *Front Nutr.* (2023) 10:1132597. doi: 10.3389/fnut.2023.1132597

19. Zhu R-C, Li F-F, Wu Y-Q, Yi Q-Y, Huang X-F. Minimal effect of sleep on the risk of age-related macular degeneration: a Mendelian randomization study. *Front Aging Neurosci.* (2023) 15:1159711. doi: 10.3389/fnagi.2023.1159711

20. Haycock PC, Burgess S, Wade KH, Bowden J, Relton C, Davey Smith G. Best (but oft-forgotten) practices: the design, analysis, and interpretation of Mendelian randomization Studies1. *Am J Clin Nutr.* (2016) 103:965–78. doi: 10.3945/ajcn.115.118216

21. Meta-analysis and Mendelian Randomization: A Review – Bowden. (2019) Research synthesis methods – Wiley online library. Available at: https://onlinelibrary. wiley.com/doi/10.1002/jrsm.1346 (Accessed September 30, 2023).

22. Avoiding Bias from weak instruments in Mendelian randomization studies – PubMed. Available at: https://pubmed.ncbi.nlm.nih.gov/21414999/ (Accessed October 2, 2023).

23. Burgess S, Thompson SG. Interpreting findings from Mendelian randomization using the MR-egger method. Eur J Epidemiol. (2017) 32:377–89. doi: 10.1007/s10654-017-0255-x

24. The MRC IEU OpenGWAS Data Infrastructure | bioRxiv. Available at: https:// www.biorxiv.org/content/10.1101/2020.08.10.244293v1 (Accessed September 29, 2023).

25. Bowden J, Davey Smith G, Burgess S. Mendelian randomization with invalid instruments: effect estimation and bias detection through egger regression. *Int J Epidemiol.* (2015) 44:512–25. doi: 10.1093/ije/dyv080

26. Ong J-S, MacGregor S. Implementing MR-PRESSO and GCTA-GSMR for pleiotropy assessment in Mendelian randomization studies from a practitioner's perspective. *Genet Epidemiol.* (2019) 43:609–16. doi: 10.1002/gepi.22207

27. Triangulation in Aetiological Epidemiology | International journal of epidemiology | Oxford Academic. Available at: https://academic.oup.com/ije/article/45/6/1866/2930550 (Accessed October 12, 2023).

28. Sanderson E, Davey Smith G, Windmeijer F, Bowden J. An examination of multivariable Mendelian randomization in the single-sample and two-sample summary data settings. *Int J Epidemiol.* (2019) 48:713–27. doi: 10.1093/ije/dyy262

29. Zhang C, Wu H-B, Cheng M-X, Wang L, Gao C-B, Huang F. Association of exposure to multiple metals with papillary thyroid Cancer risk in China. *Environ Sci Pollut Res Int.* (2019) 26:20560–72. doi: 10.1007/s11356-019-04733-x

30. Thyroid Function and Serum Copper, Selenium, and zinc in general U.S. population | SpringerLink. Available at: https://link.springer.com/article/10.1007/ s12011-014-9992-9 (Accessed October 3, 2023).

31. Anderson CP, Shen M, Eisenstein RS, Leibold EA. Mammalian Iron metabolism and its control by iron regulatory proteins. *Biochim Biophys Acta*. (2012) 1823:1468–83. doi: 10.1016/j.bbamcr.2012.05.010

32. Wopereis DM, Du Puy RS, van Heemst D, Walsh JP, Bremner A, Bakker SJL, et al. The relation between thyroid function and Anemia: a pooled analysis of individual participant data. *J Clin Endocrinol Metabol.* (2018) 103:3658–67. doi: 10.1210/ jc.2018-00481

33. Betsy A, Binitha M, Sarita S. Zinc deficiency associated with hypothyroidism: an overlooked cause of severe alopecia. *Int J Trichology*. (2013) 5:40–2. doi: 10.4103/0974-7753.114714

34. Hormones.Gr. Available at: http://www.hormones.gr/698/article/relationshipbetween-serum-zinc-levels-thyroid%E2%80%A6.html (Accessed October 3, 2023).

35. Baltaci AK, Mogulkoc R, Belviranli M. L-thyroxine-induced hyperthyroidism affects elements and zinc in rats. *Bratisl Lek Listy*. (2013) 114:125–8. doi: 10.4149/ BLL\_2013\_027

36. Ambali SF, Orieji C, Abubakar WO, Shittu M, Kawu MU. Ameliorative effect of vitamin C on alterations in thyroid hormones concentrations induced by subchronic Coadministration of Chlorpyrifos and lead in Wistar rats. *J Thyroid Res.* (2011) 2011:e214924:1–6. doi: 10.4061/2011/214924

37. Jubiz W, Ramirez M. Effect of vitamin C on the absorption of levothyroxine in patients with hypothyroidism and gastritis. *J Clin Endocrinol Metabol.* (2014) 99:E1031-4. doi: 10.1210/jc.2013-4360

38. Chahardoli R, Saboor-Yaraghi A-A, Amouzegar A, Khalili D, Vakili AZ, Azizi F. Can supplementation with vitamin D modify thyroid autoantibodies (anti-TPO ab, anti-Tg ab) and thyroid profile (T3, T4, TSH) in Hashimoto's thyroiditis? A double blind, randomized clinical trial. *Horm Metab Res.* (2019) 51:296–301. doi: 10.1055/a-0856-1044

39. Bennett DA, Holmes MV. Mendelian randomisation in cardiovascular research: an introduction for clinicians. *Heart.* (2017) 103:1400–7. doi: 10.1136/ heartjnl-2016-310605